---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-23-000161"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:18:26.234945+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q3 2023 revenue up 19% to $90.1M; net loss widens on $34.9M impairment

## Summary
- Total revenue $90.1M, +19% YoY; testing revenue $82.0M, +27% YoY.
- Net loss $29.6M ($0.41 per share) vs $8.7M loss a year ago; includes $34.9M impairment from nCounter license.
- Total test volume 32,544, +23% YoY.
- Non-GAAP gross margin 69% vs 66% prior year; generated $14.2M cash from ops, cash $202.5M.
- Management cites strong demand for Decipher Prostate and Afirma tests driving growth.

## SEC filing metadata
- accession: 0001384101-23-000161
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/0001384101-23-000161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/vcyt-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-23-000161
- JSON: https://secwatch.observer/filing/0001384101-23-000161.json
- Plain text: https://secwatch.observer/filing/0001384101-23-000161.txt

## Key facts
- Earnings Releases
  VERACYTE, INC. reported the third quarter ended September 30, 2023 results: revenue $90.1 million, net income Net loss for the third quarter of 2023 was $29.6 million, EPS $0.41.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $90.1 million
  - Net income: Net loss for the third quarter of 2023 was $29.6 million
  - EPS: $0.41
  - Result: reported results
  source text: EX-99.1 (EX-99.1 PRESS RELEASE 11-07-2023) --- PRESS RELEASE 11-07-2023 Document Exhibit 99.1 Veracyte Announces Third Quarter 2023 Financial Results Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., November 7, 2023 --- Veracyte, Inc. (Nasdaq: VCYT)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1384101/000138410123000161/0001384101-23-000161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.